Day: July 15, 2020

Dėl COVID-19 viruso pandemijos jos sukeltų apribojimų birželį „Novaturo“ grupė organizuojamų kelionių laikinai nevykdė. Tuo pat metu pernai Bendrovės apyvarta sudarė 16,6 mln. eurų, aptarnautų klientų skaičius siekė 31,8 tūkst.Laisvėjant ribojimams, „Novaturo“ grupė iš visų Baltijos šalių rinkų jau nuo liepos 1 d. atnaujino dalį poilsinių kelionių į Graikiją ir poilsiautojus skraidina į Kretos, Rodo ir Korfu kurortus. Bendrovė tikisi, kad ribojimams ir toliau švelnėjant, savo klientams galės pasiūlyti daugiau saugių atostogauti krypčių. Artimiausiu metu planuojama atnaujinti ir pažintines kelionės po Europos šalis. Norintiems atostogauti arčiau namų, Bendrovė siūlo rinktis poilsį Baltijos šalių kurortuose.Atnaujinus kelionių vykdymą, Bendrovė fiksavo išaugusį susidomėjimą paskutinės minutės kelionių pasiūlymais, augo ir kitų metų vasaros...

AB Amber Grid, legal entity code: 303090867. Address: Savanorių pr. 28, LT-03116 Vilnius, Lithuania.Amber Grid (hereafter, the Company) hereby informs that on 22nd of June 2020 UAB EPSO-G Audit Committee (which also acts as Company‘s Audit Committee) expressed an opinion about the amendment of the contract which Company’s subsidiary UAB GET Baltic is willing to conclude with UAB EPSO-G regarding the lending and borrowing contract signed between EPSO-G and the Company subsidiary on 31st of March 2019 (hereafter, the Agreement):More information:Laura Šebekienė, Head of Communications of Amber Grid,ph. +370 699 61 246, e-mail: l.sebekiene@ambergrid.lt

Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to PlaceboLive Webinar with Study Investigators on Thursday, July 16th, from 4:00-5:00 pm EDTWARREN, N.J., July 15, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that results from Cohort 1 of the iNO-PF Phase 2/3 Study will be published in the August 2020 edition of the peer-reviewed CHEST Journal, the official publication of the American College of Chest Physicians, and the Chief Medical Officer of Bellerophon, Hunter Gillies, M.D., will participate in a webinar with study investigators to discuss clinical implications of the data. The iNO-PF study evaluated safety and efficacy in patients at...

LAS VEGAS, July 15, 2020 (GLOBE NEWSWIRE) — Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) is pleased to announce the 2nd monthly release and distribution of the July edition of its Microdose Monthly newsletter, which features three articles that provide an overview of Kevin O’Leary’s investment participation with MindMed, a review of Gwyneth Paltrow’s Goop Lab on Netflix, and an exclusive one-on-one interview with Chi Psilocybin, a prominent voice for the psychedelic reform movement and owner of Truffles Therapy in Amsterdam.The interview with Chi, amply titled “A Servant of the Mushroom Kingdom,” is an in-depth look at a personal journey and discovery of the benefits associated with a life-long affinity for psychedelics and finding life’s passion and purpose. On a trip to Thailand, Chi met his future...

SOLANA BEACH, Calif., July 15, 2020 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has initiated the commercial manufacturing of Gimoti™ (metoclopramide) nasal spray with its manufacturing partner, Patheon, a division of Thermo Fisher Scientific, Inc. Gimoti was approved by the U.S. Food and Drug Administration on June 19, 2020 for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The Company plans to launch sales of Gimoti in the fourth quarter 2020 with its partner EVERSANA.“We have continued to accelerate the necessary pre-commercialization activities for Gimoti alongside our commercial and manufacturing partners,” said David Gonyer, R.Ph., President and CEO. “Together with...

VANCOUVER, British Columbia, July 15, 2020 (GLOBE NEWSWIRE) — Deer Horn Capital Inc. (CSE: DHC) (the “Company” or “Deer Horn”) is pleased to announce that, together with Cheona Metals, the joint mineral prospecting program originally announced on May 25, 2020 has been completed in northern British Columbia. The program was led by Dr. Lee Groat of the University of British Columbia and Tahltan entrepreneur Allen Edzerza.  Results from the prospecting are pending.Cheona Metals, in which Deer Horn holds a 49% interest, was formed to help Indigenous peoples achieve social and economic independence through exercise of their inherent rights and title to mineral resources in their ancestral lands. Cheona explores for minerals in Indigenous territories of British Columbia and Yukon. Cheona also works with government, NGO, Indigenous and...

Contract received for AC inverters is second project at Bonneville Lock and DamWARWICK, NY., July 15, 2020 (GLOBE NEWSWIRE) — Ozop Surgical Corp (OZSC), (“Ozop” or the “Company”), announced today that its wholly owned subsidiary, Power Conversion Technologies, Inc. (PCTI), has received an order through a third party for support with a large renewable energy project managed by the U.S. Army Corps of Engineers. PCTI will develop and deliver highly specialized DC/AC converters for use at the Bonneville Lock and Dam, a hydroelectric power generating plant in the Columbia River Gorge.The project has features rarely seen in the power industry, including dual high current, low voltage DC inputs, at a higher output power rating, which require the use of some of the largest integrated power modules available today. This purchase marks the...